MedTrace Logo

A Study of LY2624803 in Japanese Participants With Transient Insomnia

NCT01784614 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-01-28

Study results available
· View outcomes & findings →

Summary

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods. Participants will receive a single dose of LY2624803 or placebo in each treatment period.

Conditions

  • Sleep Initiation and Maintenance Disorders

Interventions

DRUG

LY2624803 - Solution

Administered orally as reconstituted solution

DRUG

LY2624803 - Capsule

Administered orally as a capsule

DRUG

Placebo - Solution

Administered orally as solution

DRUG

Placebo - Capsule

Administered orally as a capsule

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01784614 on ClinicalTrials.gov